News & Updates

A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.

First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.

Women on testosterone therapy (TTh) show a lower risk of major adverse cardiac events (MACE) than matched controls, while postmenopausal women have a comparable MACE risk and a similar or significantly reduced risk of breast cancer on age-based subanalysis, reports a study.